Adicet Bio Inc (ACET)
NASDAQ:ACET
Want to see ACET full AI Analyst Report?
ACET Stock Chart & Stats
$8.22
-$0.04(-4.07%)
At close: 4:00 PM EST
$8.22
-$0.04(-4.07%)
Day’s Range― - ―
52-Week Range$6.01 - $17.43
Previous CloseN/A
Volume197.46K
Average Volume (3M)108.05K
Market Cap
$87.03M
Enterprise Value$64.69M
Total Cash (Recent Filing)$137.59M
Total Debt (Recent Filing)$13.90M
Price to Earnings (P/E)―
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
-2.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-14.90
Shares Outstanding9,348,236
10 Day Avg. Volume127,231
30 Day Avg. Volume108,046
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-48.20
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$34.83Price Target Upside323.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-8.34
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLow absolute debt (~$13.9M) and a ~0.10 debt-to-equity ratio give Adicet durable financial flexibility. With limited interest burden the company can prioritize R&D and clinical programs, absorb near-term shocks, and pursue partnerships or opportunistic financing without heavy leverage constraints.
Proprietary Platform FocusA focused allogeneic γδ T‑cell platform offers a structural advantage: off‑the‑shelf manufacturing can scale faster and potentially reduce per‑patient costs versus autologous approaches. If clinical efficacy is demonstrated, this platform can enable broader addressable markets across hematologic and solid tumors.
Institutional Investor Support / Financing OptionalityA structured exchange with RA Capital signals institutional willingness to provide capital and optionality. The pre‑funded warrant and capped ownership preserve governance while leaving a pathway for future funded participation, which supports multi‑quarter program financing without immediate concentrated control shifts.
Bears Say
No Product Revenue / Large Net LossesZero product revenue and ~ $109M net loss in the trailing twelve months underscore that operations depend on financing, not sales. This structural lack of operating income means long‑term viability hinges on clinical success or partnerships, increasing execution risk over the next several quarters.
Eroding Equity BaseA halved equity base over a few years reduces the company's capital cushion and its ability to absorb further R&D losses. This structural depletion can worsen financing terms, increase dilution pressure on new raises, and limit strategic flexibility during multi‑year clinical development cycles.
Sustained Cash BurnPersistent ~-$90M operating and free cash flow implies ongoing reliance on external capital. Such a high burn rate constrains consistent program funding, may necessitate frequent equity raises that dilute shareholders, and risks program delays or prioritization cuts absent partnership or approval milestones.
Adicet Bio News
ACET FAQ
What was Adicet Bio Inc’s price range in the past 12 months?
Adicet Bio Inc lowest stock price was $6.01 and its highest was $17.43 in the past 12 months.
What is Adicet Bio Inc’s market cap?
Adicet Bio Inc’s market cap is $87.03M.
When is Adicet Bio Inc’s upcoming earnings report date?
Adicet Bio Inc’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Adicet Bio Inc’s earnings last quarter?
Adicet Bio Inc released its earnings results on May 13, 2026. The company reported -$1.88 earnings per share for the quarter, beating the consensus estimate of -$3.076 by $1.196.
Is Adicet Bio Inc overvalued?
According to Wall Street analysts Adicet Bio Inc’s price is currently Undervalued.
Does Adicet Bio Inc pay dividends?
Adicet Bio Inc pays a Quarterly dividend of $0.01 which represents an annual dividend yield of N/A. See more information on Adicet Bio Inc dividends here
What is Adicet Bio Inc’s EPS estimate?
Adicet Bio Inc’s EPS estimate is -2.18.
How many shares outstanding does Adicet Bio Inc have?
Adicet Bio Inc has 9,348,236 shares outstanding.
What happened to Adicet Bio Inc’s price movement after its last earnings report?
Adicet Bio Inc reported an EPS of -$1.88 in its last earnings report, beating expectations of -$3.076. Following the earnings report the stock price went up 4.213%.
Which hedge fund is a major shareholder of Adicet Bio Inc?
Currently, no hedge funds are holding shares in ACET
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.83 (323.76% Upside)
$34.83 (323.76% Upside)
Blogger Sentiment
Bullish
ACET Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 77.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $929.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.32%
12-Months-Change
Fundamentals
Return on Equity
-80.35%
Trailing 12-Months
Asset Growth
-11.44%
Trailing 12-Months
Company Description
Adicet Bio Inc
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
ACET Stock 12 Month Forecast
Average Price Target
$34.83
▲(323.76% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―
Ownership Overview
22.02% Insiders
9.72% Mutual Funds
44.52% Other Institutional Investors
20.24% Public Companies and
Individual Investors